Federal Appeals Court Restricts Mail Distribution of Abortion Pill Mifepristone
The 5th U.S. Circuit Court of Appeals has ruled that mifepristone must be dispensed in person at clinics, blocking its distribution by mail and affecting nationwide access to the abortion pill.
A federal appeals court has mandated that mifepristone, a widely used abortion pill, be dispensed exclusively in person at clinics, effectively prohibiting its distribution by mail. The unanimous decision from the 5th U.S. Circuit Court of Appeals overrides existing FDA regulations that permitted mailing the medication.
The ruling is expected to be appealed to the U.S. Supreme Court. Judge Kyle Duncan, appointed by President Donald Trump, stated that allowing the drug to be mailed undermines Louisiana's abortion ban, noting that "every abortion facilitated by FDA's action cancels Louisiana's ban on medical abortions and undermines its policy that 'every unborn child is human being from the moment of conception and ... .'"
Mifepristone, approved by the FDA in 2000, is commonly used in combination with misoprostol to terminate early pregnancies. The appeals court's decision affects all states, including those without abortion restrictions, and has been described as the most significant federal restriction on abortion access since the overturning of Roe v. Wade in 2022.
Danco Laboratories, a manufacturer of mifepristone, has petitioned the U.S. Supreme Court to block the appellate court's ruling while appeals are pending. The outcome of this case could have far-reaching implications for abortion access and is likely to influence political discourse ahead of the upcoming midterm elections.